311 related articles for article (PubMed ID: 32441379)
21. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
24. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D; Gerbitz A; Ayuk F; Kiani A; Hildebrandt GC; Vogelsang GB; Elad S; Lawitschka A; Socie G; Pavletic SZ; Holler E; Greinix H
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1611-28. PubMed ID: 20601036
[TBL] [Abstract][Full Text] [Related]
25. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
26. Graft-versus-host disease management.
Mistrik M; Bojtarova E; Sopko L; Masakova L; Roziakova L; Martinka J; Batorova A
Bratisl Lek Listy; 2016; 117(7):388-96. PubMed ID: 27546540
[TBL] [Abstract][Full Text] [Related]
27. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Jaglowski SM; Blazar BR
Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
[TBL] [Abstract][Full Text] [Related]
28. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
Dietrich-Ntoukas T; Cursiefen C; Westekemper H; Eberwein P; Reinhard T; Bertz H; Nepp J; Lawitschka A; Heiligenhaus A; Seitz B; Messmer EM; Meyer-ter-Vehn T; Basara N; Greinix H; Datiles MB; Lee SJ; Pavletic SZ; Wolff D
Cornea; 2012 Mar; 31(3):299-310. PubMed ID: 22157574
[TBL] [Abstract][Full Text] [Related]
31. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
32. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
33. [Prophylaxis and treatment of chronic graft versus host disease].
Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
[TBL] [Abstract][Full Text] [Related]
34. Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
Wolff D; Hilgendorf I; Wagner-Drouet E; Jedlickova Z; Ayuk F; Zeiser R; Schäfer-Eckart K; Gerbitz A; Stadler M; Klein S; Middeke JM; Lawitschka A; Winkler J; Halter J; Holler E; Kobbe G; Stelljes M; Ditschkowski M; Greinix H
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1450-1455. PubMed ID: 30876928
[TBL] [Abstract][Full Text] [Related]
35. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
36. GVHD Prophylaxis 2020.
Gooptu M; Antin JH
Front Immunol; 2021; 12():605726. PubMed ID: 33897681
[TBL] [Abstract][Full Text] [Related]
37. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
40. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
